Market revenue in 2023 | USD 1,537.1 million |
Market revenue in 2030 | USD 2,137.4 million |
Growth rate | 4.8% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 64.26% in 2023. Horizon Databook has segmented the U.S. pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is the largest market for pancreatic cancer diagnostic tests in North America, due to the high cancer prevalence in the country and consequent rapid adoption of cancer diagnostic tests. Furthermore, significant technological advancements, an increasing number of FDA approvals for tests, and competition among biotechnology companies are projected to boost the market over the forecast period.
Pancreatic cancer rates in the U.S. are rising steadily. This trend reflects increasing awareness and improved detection methods, though challenges in early diagnosis persist. Research and public health efforts are crucial in addressing this concerning trend.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into U.S. pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account